Role of endocrine responsiveness and HER2/neu overexpression in inflammatory breast cancer treated with multimodality preoperative therapy

Breast Journal

Volumn 14, Issue 5, 2008, Pages 435-441

  D'Alessandro, Claudia ^a   Dellapasqua, Silvia ^a   Orlando, Laura ^a   Santoro, Luigi ^a   Maisonneuve, Patrick ^a   Torrisi, Rosalba ^a   Balduzzi, Alessandra ^a   Scarano, Eloise ^a   Ghisini, Raffaella ^a   Peruzzotti, Giulia ^a   Goldhirsch, Aron ^a   Colleoni, Marco ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Inflammatory breast cancer; Nonendocrine responsive breast cancer; Preoperative therapy

Indexed keywords

CEFAZOLIN; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; LETROZOLE; PROGESTERONE RECEPTOR; TRIPTORELIN;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER GRADING; CANCER HORMONE THERAPY; CANCER REGRESSION; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG SUBSTITUTION; FEMALE; GENE OVEREXPRESSION; HAND FOOT SYNDROME; HUMAN; HUMAN CELL; INFLAMMATION; LEUKOPENIA; MASTECTOMY; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; ONCOGENE NEU; PREMENOPAUSE; PREOPERATIVE CARE; SKIN TOXICITY; TREATMENT OUTCOME; VOMITING;

ADULT; AGE FACTORS; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, NEEDLE; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COMBINED MODALITY THERAPY; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MASTECTOMY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM STAGING; POSTMENOPAUSE; PREMENOPAUSE; PROBABILITY; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 51349086422     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2008.00619.x     Document Type: Article

References (35)

1. Chang S, Parker SL, Pham T, et al. Inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute, 1975-1992. Cancer 1998 82 : 2366 72.
2. Fastenberg NA, Martin RG, Buzdar AU, et al. Management of inflammatory carcinoma of the breast. A combined modality approach. Am J Clin Oncol 1985 8 : 134 41.
3. Cance WG, Carey LA, Graham M 2nd. Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival. Ann Surg 2002 236 : 295 302 discussion 302-3.
4. Chevallier B, Bastit P, Graic Y, et al. The Centre H. Becquerel studies in inflammatory non metastatic breast cancer. Combined modality approach in 178 patients. Br J Cancer 1993 67 : 594 601.
5. Ueno NT, Buzdar AU, Singletary SE, et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol 1997 40 : 321 9.
6. de Boer RH, Saini A, Johnston SR, et al. Continuous infusional combination chemotherapy in inflammatory breast cancer: a phase II study. Breast 2000 9 : 149 55.
7. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998 16 : 2672 85.
8. Colleoni M, Zarieh D, Gelber R, Viale G, Luini A, Veronesi P. Preoperative systemic treatment: prediction of responsiveness. Breast 2003 12 : 538 5421.
9. Colleoni M, Viale G, Zahrieh D, et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 2004 10 : 6622 8.
10. Rocca A, Peruzzotti G, Ghisini R, et al. A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer. Anticancer Drugs 2006 17 : 1201 9.
11. Colleoni M, Curigliano G, Minchella I, et al. Preoperative and perioperative chemotherapy with 5-fluorouracil as continuous infusion in operable breast cancer expressing a high proliferation fraction: cytotoxic treatment during the surgical phase. Ann Oncol 2003 14 : 1477 83.
12. Kuerer HM, Newman LA, Smith TM, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999 17 : 460 9.
13. Chevallier B, Asselain B, Kunlin A, Veyret C, Bastit P, Graic Y. Inflammatory breast cancer. Determination of prognostic factors by univariate and multivariate analysis. Cancer 1987 60 : 897 902.
14. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958 53 : 457 81.
15. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation on each patient. II. Analysis and examples. Br J Cancer 1977 35 : 1 39.
16. Cox DR. Regression models and life-tables (with discussion). J R Stat Soc Ser B 1972 34 : 187 220.
17. Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU, et al. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. Clin Breast Cancer 2004 4 : 415 9.
18. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003 21 : 4165 74.
19. Van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002 347 : 1999 2009.
20. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001 98 : 10869 74.
21. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005 16 : 1569 83.
22. Early Breast Cancer Trialists' collaborative Group (EBCTTG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005 365 : 1687 717.
23. Coates A, Keshaviah A, Thürlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of Study BIG 1-98. J Clin Oncol 2007 25 : 486 92.
24. Ellis M, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001 19 : 3795 7.
25. Tassone P, Tagliaferri P, Perricelli A, et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 2003 88 : 1285 91.
26. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005 353 : 1659 72.
27. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005 353 : 1673 84.
28. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. 28th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, Dec 7-10, 2005 [Abstract].
29. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006 354 : 809 20.
30. Smith I, Procter M, Gelber RD, et al. for the HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet 2007 369 : 29 36.
31. Limentani SA, Brufsky AM, Erban JK, et al. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer. J Clin Oncol 2007 25 : 1232 8.
32. Hurley J, Doliny P, Reis I, et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 2006 24 : 1831 8.
33. Buzdar AU, Valero V, Ibrahim NK, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005 23 : 3676 85.
34. Buzdar AU, Valero V, Ibrahim NK, Francis DN, Broglio KR, Theriault RL. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007 13 : 228 33.
35. Gianni L, Semiglazov V, Manikhas GM, et al. Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): antitumour and safety analysis. J Clin Oncol ASCO Annu Meet Proc 2007 25 : 532.